MedTrace Logo

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT00429936 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2010-06-22

No results posted yet for this study

Summary

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

Conditions

Interventions

DRUG

Fenretinide

Once daily 30 minutes after the evening meal for 24 months

Sponsors & Collaborators

  • ReVision Therapeutics, Inc.

    collaborator OTHER

  • Sirion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Vogel, MD · ReVision Therapeutics Advisor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-05-31
Completion
2010-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429936 on ClinicalTrials.gov